期刊文献+

我国罕用药供应的管理 被引量:4

下载PDF
导出
摘要 罕见病(Rare Disease)指受累人数占国民总人口比例较低的疾病,尚无严格、科学和世界公认的具体定义,以各国国情及人口基数不同而有差异,美国规定国内发病少于20万人(占总人口的0.75%0)疾病为罕见病。罕见病疾病谱主要包括遗传性疾病、癌症、传染病、急性中毒等。罕用药(Orphan Drug)主要是指用于治疗、预防、诊断罕见疾病的药物、疫苗、诊断试剂等。由于罕用药临床用量小,药品商业价值低特点,市场经济条件下,仅靠市场机制调节难以保障罕用药供给。政府部门有必要对罕用药供应使用进行宏观调控,施行特殊管理,保证急救药等罕用药的临床供应。
作者 张建国
机构地区 高密市人民医院
出处 《药物流行病学杂志》 CAS 2008年第5期342-343,共2页 Chinese Journal of Pharmacoepidemiology
  • 相关文献

参考文献4

二级参考文献16

  • 1万仁甫,徐伟亚.建立医院罕见病信息管理制度的思考[J].中华医院管理杂志,2006,22(4):275-278. 被引量:11
  • 2USA. Orphan Drug Act [M]. Pub Law USC, 1983, (4) : 97- 414.
  • 3Thamer M,Brenan N,Srmansky R. A cross national Comparison of orphan drug policies: implications for the US Orphan Drug Act[J]. J Health polit policy law, 1998,23(2) :265-269.
  • 4Meyers AS. Orphan Drugs:the current situation in the United States,Europe,and Asia[J]. Drug Inf J,1997,31(1) :101-105.
  • 5Meyers AS. History of the American Orphan Drug Act [R]. In ternational conference of rare disease and orphan drugs. Spain, 2000.
  • 6[1]Orphan Drug Act. Pub Law, USC. 1983(97-414 as amended)
  • 7[2]The Orphan Drug Regulations. FDA.21 CFR Part 316, 1992,57FR62076
  • 8[3]John H. Orphan drug Law matures into medical mainstay. FDA Consumer, 1999,33(3):189
  • 9[4]Michael A. Europe proposes orphan drug legislation. Nature Biotechnology, 1998,16(9):814
  • 10Haffner ME.Orphan drug development-International program and study design issues.Drug Inf J,1998,32:93-99.

共引文献12

同被引文献51

  • 1万仁甫,徐伟亚.建立医院罕见病信息管理制度的思考[J].中华医院管理杂志,2006,22(4):275-278. 被引量:11
  • 2Linthorst G,Hollak C.European ordinance on orphan drugs:changes and threats[J].Ned Tijdschr Geneeskd,2003,147(4):143-145.
  • 3Scott D.Orphan drug programs/policies in Australia,Japan,and Canada[J].Drug Inf J,2001,35 (1):11-13.
  • 4Haffner ME.The Food and Drug Administration's Office of Orphan Products Development:incentives,grants,and special designations speed therapies for orphan diseases[J].Retina,2005,25(8 Suppl):89-90.
  • 5Heemstra H,Vrueh R.Predictors of orphan drug approval in the European Union[J].Eur J Clin Pharmacol,2008,64 (5):545-552.
  • 6Thoene JG.Orphan drugs and orphan tests in the USA[J].Community Genet,2004,7(4):169-172.
  • 7Trouiller P,Rey J,Bouscharain P.Pharmaceutical development concerning diseases predominating in tropical regions:the concept of indigent drugs[J].Ann Pharm Fr,2000,58(1):43-44.
  • 8Makoto S,Kiyohito N.Development of orphan drugs in Japan:characteristics of orphan drugs developed in Japan[J].Drug Inf J,2000,34(3):839-841.
  • 9国家食品药品监督管理局.药品注册管理办法(局令第28号).2007-07-10.
  • 10Scheindlin S.Rare diseases-orphan drugs and orphaned patients[J].Mol Interv.2006,6(4):186-191.

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部